Protocol Ledger

NCT06677853 · Phase II/III · COMPLETED

Timolol Maleate Gel for the Treatment of Infantile Hemangioma

Interventional Phase II/III clinical trial protocol NCT06677853 sponsored by Auson Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-28 Enrollment: 168 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06677853
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)168 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06677853
Protocol FieldVerified Registry Value
NCT IdentifierNCT06677853
Consolidated Lead SponsorAuson Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment168 participants (ACTUAL)
Registered Start Date2020-10-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06677853
Hospital Research SiteLocationSite Profile
Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI